With the emergence of flortaucipir (FTP) (a.k.a. AV-1451) positron emission tomography (PET) measurements tracking tau uptake and their incorporation in the third phase of the Alzheimer’s Disease Neuroimaging Initiative (ADNI3), several studies have explored the link between tau accumulation in the context of amyloid deposition and other neuroimaging and neuropathologic correlates [15–20]. Here, MAPT is linked to amyloidosis.